Answers are grounded in this paper and cite their sources.
Randomized noninferiority trial demonstrates noninferior cardiovascular safety of testosterone-replacement therapy in men with hypogonadism, indicating comparable risk to placebo.
In men with hypogonadism and preexisting or a high risk of cardiovascular disease, testosterone-replacement therapy was noninferior to placebo with respect to the incidence of major adverse cardiac events. (Funded by AbbVie and others; TRAVERSE ClinicalTrials.gov number, NCT03518034.).
No takes yet. Share an insight, caveat, or question.
Lincoff et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: